Hologic, Inc. (NASDAQ:HOLX) Q4 2023 Earnings Call Transcript November 9, 2023 4:30 PM ET
Company Participants
Ryan Simon - Vice President, Investor Relations
Stephen MacMillan - Chairman, President and Chief Executive Officer
Conference Call Participants
Puneet Souda - Leerink Partners
Jack Meehan - Nephron Research
Derik De Bruin - Bank of America
Patrick Donnelly - Citi
Timothy Daley - Wells Fargo
Anthony Petrone - Mizuho Group
Casey Woodring - JPMorgan
Navann Ty - BNP Paribas Exane
Michael Matson - Needham & Company
Andrew Brackmann - William Blair
Andrew Cooper - Raymond James
Operator
Good afternoon, and welcome to the Hologic Fourth Quarter Fiscal 2023 Earnings Conference Call. My name is Cynthia and I am your operator for today's call. Today's conference is being recorded. All lines have been placed on mute.
I would now like to introduce Ryan Simon, Vice President, Investor Relations to begin the call. Please go ahead, sir.
Ryan Simon
Thank you, Cynthia. Good afternoon, and thank you for joining Hologic's fourth quarter fiscal 2023 earnings call. With me Today is Steve MacMillan, the company's Chairman, President, and Chief Executive Pfficer; Karleen Oberton, our Chief Financial Officer, is currently on bereavement and will not be joining us today. Karleen is with family and I will be covering for her on our call. Please join me in wishing Karleen and her family well.
Our fourth quarter press release is available now on the Investors section of our website. We will also post our prepared remarks to our website shortly after we deliver them, as well as an updated corporate presentation. And a replay of this call will be available on our website for the next 30 days.
Before we begin, we would like to inform you that certain statements we make today will be forward-looking. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Such factors include those referenced in the Safe Harbor Statement included in our earnings release and SEC filing.
Also during this call, we will discuss certain non-GAAP financial measures. A reconciliation to GAAP can be found in our earnings release. Two of these non-GAAP measures are: one, organic revenue, which we define as revenue excluding divested businesses and revenue from acquired businesses owned by Hologic for less than one year; and two, organic revenue excluding COVID-19, which excludes COVID-19 assay revenue, revenue related to COVID-19, and sales from discontinued products in diagnostics. Finally, any percentage changes we discuss will be on a year-over-year basis and revenue growth rates will be in constant currency unless otherwise noted.